TUSK THERAPEUTICS
Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the treatment of cancer. The Company has established a growing, diversified pipeline of antibodies against a selection of both novel and validated targets that play an important role in the immune response to cancer. The Company’s programmes target the tumour microenvironment and exert their action through modulatio... n, activation and/ or depletion of these immune cells. Tusk has a world-class leadership team as well as outstanding scientific advisors, including top immuno oncology researchers, and the team has extensive biotech and pharma experience in antibody discovery and drug development, with a track record of bringing drugs from early stage discovery through to approval. The Company is based at the Stevenage Bioscience Catalyst in Stevenage, UK.
TUSK THERAPEUTICS
Industry:
Health Care Therapeutics
Founded:
2014-01-01
Address:
Stevenage, Herefordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.tusktherapeutics.com
Total Employee:
11+
Status:
Closed
Total Funding:
2.5 M GBP
Technology used in webpage:
Safenames
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Founder
Investors List
Innovate UK
Innovate UK investment in Grant - Tusk Therapeutics
Official Site Inspections
http://www.tusktherapeutics.com
- Host name: redirect.idp365.net
- IP address: 217.19.248.132
- Location: Milton Keynes United Kingdom
- Latitude: 52.0675
- Longitude: -0.7569
- Timezone: Europe/London
- Postal: MK14
More informations about "Tusk Therapeutics"
Tusk Therapeutics - Crunchbase Company Profile & Funding
Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the …See details»
Tusk Therapeutics - VentureRadar
Tusk Therapeutics is a privately held immuno-oncology company focused on discovering and developing therapeutic antibodies that harness the power of the immune system to transform …See details»
Roche acquires Tusk Therapeutics in up to $759m deal
Roche has acquired UK-based immuno-oncology company Tusk Therapeutics in a deal valued at up to €655m ($759m). As per the terms of the agreement, Roche will make an upfront payment of €70m to Tusk Therapeutics, followed by …See details»
Tusk Therapeutics Company Profile 2024: Valuation, …
Tusk Therapeutics is headquartered in Hertfordshire, United Kingdom. What is the size of Tusk Therapeutics? Tusk Therapeutics has 7 total employees. What industry is Tusk Therapeutics in? Tusk Therapeutics’s primary industry is …See details»
Tusk Therapeutics - Ownership and Business Overview - Mergr
Sep 28, 2018 Tusk Therapeutics Ltd. is a privately held immuno-oncology company focused on discovering and developing therapeutic antibodies that harness the power of the immune …See details»
Tusk Therapeutics S.A. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tusk Therapeutics S.A. of Luxembourg. Get the latest business insights from Dun & Bradstreet.See details»
Tusk Therapeutics - Products, Competitors, Financials, Employees ...
Tusk Therapeutics is an immuno-oncology company, focused on discovering and developing therapeutic antibodies for the treatment of cancer. Use the CB Insights Platform to explore …See details»
Roche acquires Tusk Therapeutics - 2018-09-28 - Crunchbase
Tusk Therapeutics Tusk Tx focuses on discovering & developing unique therapeutic antibodies that harness the immune system for the treatment of cancer. Acquiring Organization: Roche …See details»
Tusk Therapeutics - Crunchbase
Tusk Tx focuses on discovering & developing unique therapeutic antibodies that harness the immune system for the treatment of cancerSee details»
Tusk Therapeutics to be acquired by Roche - stevenagecatalyst.com
Tusk Therapeutics Ltd. Luc Dochez, Chief Executive Officer [email protected]. About Tusk Therapeutics Ltd. Tusk Therapeutics is a privately held immuno-oncology company …See details»
Tusk Therapeutics Ltd - Company Profile and News
Company profile page for Tusk Therapeutics Ltd including stock price, company news, executives, board members, and contact informationSee details»
Roche Acquires Cancer Immunotherapy Developer Tusk …
Sep 28, 2018 Roche has acquired Tusk Therapeutics for up to €655 million ($759 million), Tusk said, in a “bolt-on” deal that expands the buyer’s oncology pipeline with two preclinical first-in …See details»
Roche Focuses on T Regulatory Cells in $758 Million ... - BioSpace
Sep 28, 2018 Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.). Under the terms of the acquisition, Roche is paying $81 …See details»
Tusk Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Nov 14, 2017: Grant - Tusk …See details»
Roche pays €70M upfront for Tusk’s preclinical Treg depleter
Sep 28, 2018 Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T …See details»
Tusk Therapeutics to be acquired by Roche - GlobeNewswire
Sep 28, 2018 Tusk Therapeutics to be acquired by Roche. Stevenage, United Kingdom – September 28 th 2018: Tusk Therapeutics Ltd (“Tusk”) was today acquired by Roche. Tusk …See details»
Cancer Research Technology, UCL, and Tusk Therapeutics join …
Feb 7, 2017 About Tusk Therapeutics Tusk Therapeutics is a biotechnology company with a focus on harnessing the power of the immune system to fight cancer through the development …See details»
Tusk Therapeutics presents data on to its anti-CD25 programme at …
Apr 18, 2018 Tusk Therapeutics' first-in-class anti-CD25 antibody programme was built on novel biology discovered by Tusk Therapeutics in collaboration with Dr. Quezada and his team at …See details»
Homepage - MiNK Therapeutics
MiNK Therapeutics is a cutting-edge clinical-stage company developing innovative allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.See details»